Enanta Pharmaceuticals is a biotechnology company that creates small molecule drugs primarily for the treatment of viral infections and liver diseases. The company's wholly owned research and development programs are in virology, namely respiratory syncytial virus and hepatitis B virus, and in liver disease (non-virology), namely non-alcoholic steatohepatitis and primary biliary cholangitis. Through its Collaborative Development and License Agreement with AbbVie Inc (AbbVie), the company has discovered and out-licensed to AbbVie two protease inhibitor compounds that have been clinically tested, manufactured, and commercialized by AbbVie for the treatment of hepatitis C virus.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.